DESIGN THERAPEUTICS INC (DSGN)
Health Care · Clinical-stage biopharmaceuticals / gene modulation · NASDAQ
Design Therapeutics is a clinical-stage biotech company pioneering GeneTAC® small molecules to treat rare genetic diseases like Friedreich ataxia.
What DESIGN THERAPEUTICS INC does
Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC® molecules, a novel class of small-molecule therapeutics designed to modulate gene function. The company is pioneering research and development of these GeneTAC molecules for rare genetic diseases, with a program in Friedreich ataxia currently in clinical testing. The company conducts nonclinical and clinical studies internally and through third-party research and manufacturing partners.
Themes: ["Rare genetic diseases","Gene-modulating therapeutics","Friedreich ataxia","Clinical-stage biotech"]
Fundamentals
- Price$15.42 as of 2026-07-09 close
- Market cap$963M as of 2026-07-10
- 1-year return+319.8% as of 2026-07-09 close
- Net margin-3600.0% as of 2026-07-10
- ROE-33.1% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.61 as of 2026-07-10
Key risks (from latest filing)
["Company is pre-revenue and unprofitable, with significant ongoing operating losses and dependence on capital raises to fund development","Clinical development success is uncertain; nonclinical and early clinical side-effect profiles may not be indicative of future safety profile","Reliance on third-party manufacturers and contract research organizations for product development and manufacturing"]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.